Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
DNLI/Financials
Wall Street · Earnings · Institutional Sentiment
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Denali Therapeutics Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | -5.8900 | -1.337 | 0 | 30 | -88 | -183 | -90 | -20 | -90 | -20 | 15 | 28 |
| 2019 | -0.3900 | -2.081 | 129 | 31 | -36 | -186 | -46 | -178 | -46 | -200 | 32 | 29 |
| 2020 | -2.0700 | -1.539 | 26 | 92 | -197 | 41,419 | -213 | -61 | -406 | -63 | 46 | 85 |
| 2021 | 0.6500 | -2.265 | 335 | 75 | 71 | -178 | 62 | -173 | -149 | -181 | 60 | 48 |
| 2022 | -2.3900 | -2.621 | 48 | 109 | -290 | -242 | -295 | -233 | -301 | -248 | 79 | 74 |
| 2023 | -2.6000 | -0.995 | 108 | 337 | -325 | -419 | -330 | -256 | -347 | -273 | 90 | 81 |
| 2024 | -1.0600 | -2.532 | 330 | 21 | -145 | -347 | -179 | -14 | -196 | -14 | 86 | 19 |
| 2025 | - | -2.558 | - | 70 | - | -368 | - | -47 | - | -48 | - | 65 |
| 2026 | - | -1.940 | - | 216 | - | 2.F8X | - | 2.F81 | - | 2.F811 | - | 2.F811 |
| 2027 | - | -1.540 | - | 391 | - | 1.F9X | - | 1.F91 | - | 1.F911 | - | 1.F911 |
| 2028 | - | 0.141 | - | 687 | - | 0.F10X | - | 0.F101 | - | 0.F1011 | - | 0.F1011 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Price Target Consensus
-64.271% $16.10 · MISS
Nov. 6, 2024Price Then
$27.65
Price Target
$41.15
Price Now
$25.05